Loading…
← CockpitCompetitor Analysis › OCUL Ocular Therapeutix IncOpen in the cockpit ↗

Ocular Therapeutix IncOCULCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Ophthalmology biotech using a proprietary hydrogel implant to deliver drugs inside the eye long-acting.

Momentum laggard 15
Mkt cap
$1.31B
US dollars, full cap
Free float
91%
of shares outstanding
$/day
$18.1M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 10.8%
Hurdle
n/a
no reverse DCF
Next earnings
110 days
8 Mar 2027
Close · USD$5.94
1D-1.3%
1W-10.8%
1M-10.7%
3M-46.4%
6M-26.0%
YTD-51.1%
1Y-50.0%
ATR %7.5%
Beta1.40
52w lowhigh63.9% off high

What Ocular Therapeutix does

Ophthalmology biotech using a proprietary hydrogel implant to deliver drugs inside the eye long-acting.

Dextenza, a steroid insert placed in the eyelid after cataract surgery, brings in the product revenue, but it is small beside the cost of late-stage trials for Axpaxli, so the company has depended on raising capital. Axpaxli, if approved for wet macular degeneration, would compete with repeated eye injections.

Products and services

  • Dextenza (post-surgical inflammation)
  • Axpaxli (wet AMD, in development)

Customers

  • Ophthalmologists/retina specialists

Where it sits in the supply chain

  • Ophthalmic drug delivery
  • Sustained-release hydrogel implant…
  • Retina/ocular surface drug development

What could go right

  • Axpaxli approval reducing injection frequency
  • Dextenza volume growth

What could go wrong

  • Late-stage trial/regulatory risk for Axpaxli
  • Competition from established anti-VEGF drugs

Moat: narrow (IP / patents, process know-how). Proprietary hydrogel depot technology for sustained intraocular drug release is patent-protected.

Headquarters: Bedford, Massachusetts, US · Founded: 2006 · Employees: 325

Named competitors

Ocular Therapeutix at a glance

Size Ocular Therapeutix (OCUL) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.31B, the 2064th largest of 3,085 United States companies the cockpit tracks. Shares closed at $5.94 on 18 Nov 2026.

Performance Over six months the shares fell 26.0%, against -17.3% for the median peer and -2.2% for the United States market (cap-weighted) — 6th lowest of 20 in its peer set.

Growth Revenue fell 9.7% over the last twelve months (peer median +9.2%); the operating margin is -680.9% (peer median 10.9%).

Valuation It trades at 17.0× enterprise value to sales against a peer median of 4.0× (4th most expensive of 16).

Short interest Short interest is 13.2% of the free float (30 Oct 2026).

Next results Next results expected around 8 Mar 2027 (exchange calendar; dates can move).

Relative performance

7510012521 May 202621 Aug 202618 Nov 2026Peer median 84OCUL 72
Six months, rebased to 100: Ocular Therapeutix against the median of its 20 peers (local-currency closes).

Ocular Therapeutix financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$50.4M$52.0M$63.7M$58.4M$51.5M
Revenue growth—-18%+9%+13%—
Gross profit$42.8M$45.4M$58.1M$53.2M$47.0M
EBITDA-$336M-$266M-$168M-$79.4M-$76.5M
Net income-$327M-$266M-$194M-$80.7M-$71.0M
Free cash flow-$267M-$217M-$136M-$76.3M-$63.3M
Capital expenditure$13.9M$12.0M$1.29M$6.09M$3.71M
Total debt$80.0M$77.0M$75.8M$83.4M$64.3M

Quarterly statements and history in the cockpit →

Ocular Therapeutix competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%INVAMNKD688293LBRX301263068760002099002332300181NANOAMPH226950300204GHRSGPCRAVLN002020OCUL6-month return →1-month return →
Up and to the right = strong over both horizons. Ocular Therapeutix is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%0×50×100×150×INVAMNKD688293301263002099NANO226950300204OCULRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Ocular Therapeutix is the large dot.

Ocular Therapeutix competitors and peer comparison

Head to head with its named competitors (OCUL vs REGN vs RO.SW vs EYPT)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Ocular Therapeutix OCUL$1.31B-26%-10%-681%17.0×n/a
Regeneron Pharmaceuticals REGN$97.8B+46%+19%30%5.4×-1.1%
Roche RO.SW$381B+21%-1%31%5.7×1.7%
EyePoint EYPTn/a-98%n/an/an/an/a
AbbVie ABBV$506B+35%+11%36%8.7×-0.1%

How Ocular Therapeutix compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ocular Therapeutix against its 20 peers (data as of 18 Nov 2026)
MeasureOCULPeer medianRank in peer set
1-month return-10.7%-4.1%5th lowest of 20
6-month return-26.0%-17.3%6th lowest of 20
Distance from 52-week high-63.9%-37.5%2nd lowest of 20
Revenue growth (TTM)-9.7%+9.2%3rd lowest of 16
Operating margin-680.9%10.9%lowest of 16
EV / Sales17.0×4.0×4th most expensive of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Ocular Therapeutix OCULUnited States$1.31B-26%-10%-681%17.0×n/an/a
Innoviva INVAUnited States$1.31B-17%+12%38%2.2×-17.2%+3.9%
MannKind MNKDUnited States$1.31B+25%+32%-2%4.0×n/an/a
Windward Bio WWBUnited States$1.31Bn/an/an/an/an/an/a
Shanghai OPM Biosciences 688293.SSChina$1.32B+36%+133%11%9.6×25.9%+23.1%
LB Pharmaceuticals LBRXUnited States$1.30B+43%n/an/an/an/an/a
Guangdong Taienkang Pharmaceutical 301263.SZChina$1.30B-24%+2%-2%12.8×n/an/a
Celltrion Pharm 068760.KSSouth Korea$1.33B-23%+16%12%3.0×10.2%+18.1%
Zhejiang Hisoar Pharmaceutical 002099.SZChina$1.33B-2%+9%-13%4.7×n/an/a
Zhejiang Xianju Pharmaceutical 002332.SZChina$1.28B-1%+8%11%2.0×-0.4%-1.3%
Zhejiang Jolly Pharmaceutical 300181.SZChina$1.34B-15%+17%20%3.0×3.9%+22.8%
Nanobiotix NANO.PAFrance$1.35B-32%-77%-392%146.3×n/an/a
Amphastar Pharmaceuticals AMPHUnited States$1.27B+64%+3%19%2.3×2.5%+15.5%
OliX Pharmaceuticals 226950.KSSouth Korea$1.35B-51%+27%-384%125.0×n/an/a
Staidson (Beijing) Biopharmaceuticals 300204.SZChina$1.26B-41%-24%-51%39.1×n/an/a
GH Research GHRSUnited States$1.25B-19%n/an/an/an/an/a
Sinopep-Allsino Bio Pharmaceutical 688076.SSChina$1.25B-16%+14%19%4.8×3.4%+27.9%
C.Q. Pharmaceutical 000950.SZChina$1.24B-27%-3%1%0.5×n/an/a
Structure Therapeutics, Inc. Sponsored ADR GPCRUnited States$1.24B-53%n/an/an/an/an/a
Avalyn Pharma AVLNUnited States$1.23B-1%n/an/an/an/an/a
Zhejiang Jingxin Pharmaceutical 002020.SZChina$1.39B-19%+1%19%2.1×-9.6%+4.6%

Questions

Who are Ocular Therapeutix's main competitors?
Named competitors: Regeneron (Eylea) (REGN), Roche (Genentech) (RO.SW), EyePoint Pharmaceuticals (EYPT), AbbVie (Allergan) (ABBV). The cockpit's measured peer set (industry) also includes Innoviva (INVA), MannKind (MNKD), Windward Bio (WWB), Shanghai OPM Biosciences (688293.SS), LB Pharmaceuticals (LBRX), Guangdong Taienkang Pharmaceutical (301263.SZ).
Is Ocular Therapeutix expensive compared with its peers?
On ev / sales it trades at 17.0× against a peer median of 4.0×, 4th most expensive of 16 in its peer set.
How has Ocular Therapeutix stock performed?
Over six months to 18 Nov 2026 the shares returned -26.0% against -17.3% for the median peer; over one year -50.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.